{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:34:18Z","timestamp":1791135258121,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA006927"],"award-info":[{"award-number":["CA006927"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA83639"],"award-info":[{"award-number":["P50CA83639"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA140323"],"award-info":[{"award-number":["CA140323"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.ygyno.2013.01.006","type":"journal-article","created":{"date-parts":[[2013,1,13]],"date-time":"2013-01-13T04:38:49Z","timestamp":1358051929000},"page":"86-91","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"129","author":[{"given":"R.J.","family":"Schilder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.A.","family":"Lankes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.C.","family":"Modesitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Hanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.J.","family":"Bonebrake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.K.","family":"Godwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.K.","family":"Alpaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2013.01.006_bb0005","first-page":"10","article-title":"Cancer Statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0010","series-title":"Epithelial Ovarian Cancer in Principles and Practice of Gynecologic Oncology","first-page":"895","author":"Ozols","year":"2005"},{"issue":"25","key":"10.1016\/j.ygyno.2013.01.006_bb0015","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1200\/JCO.2007.11.1088","article-title":"Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition","volume":"10","author":"Martin","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0020","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0025","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0030","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"ICON7: a phase III of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0035","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/PPO.0b013e31815a7b69","article-title":"Antiangiogenic therapy for cancer: an update","volume":"13","author":"Shojaei","year":"2007","journal-title":"Cancer J"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0040","doi-asserted-by":"crossref","first-page":"8715","DOI":"10.1158\/0008-5472.CAN-05-4665","article-title":"AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts","volume":"66","author":"Polverino","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0045","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2006.07.8170","article-title":"Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors","volume":"25","author":"Rosen","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0050","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s00280-010-1243-y","article-title":"Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors","volume":"66","author":"Fujisaka","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1056\/NEJMoa075853","article-title":"Motesanib diphosphate in progressive differentiated thyroid cancer","volume":"359","author":"Sherman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00280-010-1431-9","article-title":"Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors","volume":"68","author":"Benjamin","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0065","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.2008.18.7815","article-title":"Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer","volume":"27","author":"Schlumberger","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-09-1675","article-title":"Phase 1b study of motesenib, an oral angiogenesis inhibitor, in combination with carboplatin\/paclitaxel and\/or panitumumab for the treatment of advanced non-small cell lung cancer","volume":"16","author":"Blumenschein","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0075","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1093\/annonc\/mdq731","article-title":"A phase II, multicenter, open-label randomized study of motesanib, or bevacizumab in combination with paclitaxel and carboplatin for non-small-cell lung cancer","volume":"22","author":"Blumenschein","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0080","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1200\/JCO.2011.41.4987","article-title":"International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin\/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1","volume":"30","author":"Scaliotti","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer. National Cancer Institute of Cancer","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0090","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1740774512450101","article-title":"A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials","volume":"9","author":"Sill","year":"2012","journal-title":"Clin Trials"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0095","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2011.02.013","article-title":"A Gynecologic Oncology Group phase II trial of the protein kinase C-beta inhibitor, enzastaurin and evaluation of markers with potential predictive and prognostic value in persistent or recurrent epithelial ovarian and primary peritoneal malignancies","volume":"121","author":"Usha","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2307\/1412159","article-title":"The proof and measurement of association between two things","volume":"15","author":"Spearman","year":"1904","journal-title":"Am J Psychol"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0105","series-title":"Nonparametric statistical methods","author":"Hollander","year":"1973"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0110","series-title":"Encyclopedia of statistical sciences","first-page":"463","article-title":"Hodges-Lehmann Estimators","author":"Hodges","year":"1983"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0115","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJM199602223340803","article-title":"A reversible posterior leukoencephalopthy syndrome","volume":"334","author":"Hinchey","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0120","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1445-5994.2008.01829.x","article-title":"Reversible posterior leukoencephalopathy syndrome associated with anticancer drugs","volume":"39","author":"Marinella","year":"2009","journal-title":"Intern Med J"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0125","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11912-008-0013-z","article-title":"Reversible posterior leukoencephalopathy syndrome in cancer","volume":"10","author":"Vaughn","year":"2008","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0130","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMc052954","article-title":"Reversible posterior leukoencephalopathy syndrome and bevacizumab","volume":"354","author":"Glusker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0135","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1056\/NEJMc052954","article-title":"Reversible posterior leukoencephalopathy syndrome and bevacizumab","volume":"354","author":"Ozcan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0140","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1445-5994.2009.01908.x","article-title":"Letters to the Editor. Clinical-scientific notes. Reversible posterior leukoencephalopathy syndrome associated with sunitinib","volume":"39","author":"Chen","year":"2009","journal-title":"Intern Med J"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0145","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.neurol.2008.03.007","article-title":"Posterior reversible encephalopathy syndrome during sunitinib therapy","volume":"164","author":"Cumurciuc","year":"2008","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0150","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1200\/JCO.2006.08.4608","article-title":"Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006","volume":"24","author":"Govindarajan","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0155","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(07)70037-2","article-title":"Renal thrombotic microangiopathy caused by anti-VEGF-antibody treatment for metastatic renal-cell carcinoma","volume":"8","author":"Franji\u00e9","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0160","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/annonc\/mdm454","article-title":"Sunitiib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome","volume":"18","author":"Kapiteijn","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0165","series-title":"ASCO GI 2010 Ab # 416","first-page":"162","article-title":"Motesanib with or without panitumumab (pmab) plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer (mCRC)","author":"Tebbutt","year":"2010"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0170","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s10637-008-9144-1","article-title":"Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG706) in patients with advanced solid tumors","volume":"26","author":"Lorusso","year":"2008","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0175","first-page":"4341","article-title":"Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma","volume":"61","author":"Monestiroli","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0180","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1023\/A:1011141009812","article-title":"Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and surrogate angiogenesis markers","volume":"12","author":"Bertolini","year":"2001","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.ygyno.2013.01.006_bb0185","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.4161\/cbt.5.10.3240","article-title":"Circulating cell-free DNA: a novel biomarker for response to therapy in ovarian carcinoma","volume":"5","author":"Kamat","year":"2006","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0190","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00280-009-1103-9","article-title":"Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate","volume":"65","author":"Sawaki","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0195","first-page":"181","article-title":"Antitumor activity of motesanib in a medullary thyroid cancer model","volume":"35","author":"Coxon","year":"2012","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0200","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.bbrc.2007.04.146","article-title":"Crosstalk between VEGF-A\/VEGFR2 and GDNF\/RET signaling pathways","volume":"358","author":"Tufro","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0205","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1530\/REP-07-0405","article-title":"Glial-derived neurotrophic factor promotes ovarian primordial follicle development and cell\u2013cell interaction during folliculogenesis","volume":"135","author":"Dole","year":"2008","journal-title":"Reproduction"},{"key":"10.1016\/j.ygyno.2013.01.006_bb0210","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0736-5748(01)00042-9","article-title":"Expression of glial cell line-derived neurotrophic factor (GDNF) in the developing human fetal brain","volume":"19","author":"Koo","year":"2001","journal-title":"Int J Dev Neurosci"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813000164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825813000164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:33:12Z","timestamp":1758771192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825813000164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0090825813000164"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.01.006","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2013.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}